A Proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients with Fabry Disease
Description
This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.